Advertisement

Search Results

Advertisement



Your search for all items matches 439 pages

Showing 101 - 150


gynecologic cancers

Multitargeted Tyrosine Kinase Inhibitor Shows Activity in Small Cell Carcinoma of the Ovary

An multitargeted tyrosine kinase inhibitor used to treat leukemia has shown promise against a rare and aggressive type of ovarian cancer—small cell carcinoma of the ovary hypercalcemic type (SCCOHT)—that strikes young women and girls, according to a study led by the Translational...

gynecologic cancers

Chemoradiotherapy vs Neoadjuvant Chemotherapy and Radical Surgery in Locally Advanced Squamous Cervical Cancer

In an Indian single-center phase III trial reported in the Journal of Clinical Oncology, Gupta et al found that cisplatin-based chemoradiotherapy improved disease-free survival vs neoadjuvant chemotherapy and radical surgery in women with locally advanced squamous cervical cancer. Study Details...

gynecologic cancers

Adjuvant Chemoradiotherapy vs Radiotherapy in High-Risk Endometrial Cancer

As reported in The Lancet Oncology by de Boer et al, the phase III PORTEC-3 trial has shown no significant improvement in 5-year overall survival with adjuvant chemoradiotherapy vs radiotherapy alone in women with high-risk endometrial cancer. Adjuvant chemoradiotherapy, however, was associated...

gynecologic cancers

FDA Grants Premarket Approval to New HPV Assay

On February 14, Becton, Dickinson and Company (BD) announced it had received premarket approval from the U.S. Food and Drug Administration (FDA) for the BD Onclarity human papillomavirus (HPV) assay. The test detects 14 types of high-risk HPV from specimens collected for cervical cancer screening...

gynecologic cancers

Prexasertib in Pretreated BRCA Wild-Type High-Grade Serous Ovarian Cancer

In a phase II study reported in The Lancet Oncology by Lee et al, the investigational cell-cycle checkpoint kinase 1 and 2 inhibitor prexasertib produced responses in women with recurrent BRCA wild-type high-grade serous ovarian cancer. In the study, 28 women with measureable disease enrolled...

gynecologic cancers

Potential Effect of Excess Body Weight on Detection of Cervical Precancer

In a study reported in the Journal of Clinical Oncology, Clarke et al found that increasing body mass index (BMI) was associated with lower rates of cervical precancer diagnosis and higher rates of cervical cancer diagnosis. The investigators had hypothesized that increased body mass could decrease ...

breast cancer
colorectal cancer
gynecologic cancers
hepatobiliary cancer
lung cancer
pancreatic cancer
gastroesophageal cancer

Detecting and Localizing Eight Cancer Types With One Multianalyte Blood Test

Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and also helps identify the location of the cancer. The test, called CancerSEEK, is a unique noninvasive, multianalyte test that simultaneously evaluates levels of eight cancer...

gynecologic cancers

Addition of Hyperthermic Intraperitoneal Chemotherapy to Cytoreductive Surgery in Advanced Ovarian Cancer

In a Dutch/Belgian phase III trial reported in The New England Journal of Medicine by van Driel et al, the addition of hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery following neoadjuvant chemotherapy was associated with significantly improved recurrence-free and...

breast cancer
gynecologic cancers
cost of care

Population-Based Screening for Breast and Ovarian Cancer Genetic Mutations Appears Cost-Effective

The cost-effectiveness of population-based panel testing for the known high- and moderate-penetrance ovarian and breast cancer mutations, including BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, and PALB2, was not known. Now, a study evaluating the cost-effectiveness of screening the general population for...

gynecologic cancers

Addition of Pazopanib to Paclitaxel in Persistent or Recurrent Ovarian Cancer

In a phase II trial reported in JAMA Oncology, Richardson et al found that the addition of pazopanib to paclitaxel did not improve progression-free survival among women with persistent or recurrent ovarian cancer. Study Details In the double-blind study, 106 women from 26 U.S. study sites with...

gynecologic cancers

FDA Accepts sNDA for Rucaparib in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

On December 5, Clovis Oncology announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for rucaparib (Rubraca) and granted Priority Review status to the application, with a Prescription Drug User Fee Act (PDUFA) date of April 6, 2018. In...

gynecologic cancers

Predictors of Cervical Precancer Treatment Failure

In a meta-analysis reported in The Lancet Oncology, Arbyn et al found that posttreatment high-risk human papillomavirus (HPV) testing was a better predictor of recurrence of high-grade cervical intraepithelial neoplasia of grade 2 or higher (CIN2+) than incomplete cervical excision. Study Details ...

gynecologic cancers

Immunotherapy in PD-L1–Positive Advanced Cervical Cancer

Pembrolizumab (Keytruda) treatment was active in patients with programmed cell death ligand 1 (PD-L1)–positive advanced cervical cancer enrolled in the phase Ib KEYNOTE-028 trial. The findings were reported by Frenel et al in the Journal of Clinical Oncology. Study Details In the advanced...

gynecologic cancers

Study Finds HPV Screening May Be More Sensitive Than Pap Test for Detecting Cervical Cancer

The main goal of cervical screening programs is to detect and treat precancer before the cancer develops. Human papillomavirus (HPV) testing is more sensitive than cytology for detecting precancer. However, reports of rare HPV-negative, cytology-positive cancers are motivating the continued use of...

gynecologic cancers

FDA Accepts sBLA for Bevacizumab as a Front-Line Treatment for Advanced Ovarian Cancer

On October 25, Genentech announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for bevacizumab (Avastin) in combination with chemotherapy (carboplatin and paclitaxel), followed by bevacizumab alone, for the front-line ...

gynecologic cancers

Novel Adverse Genomic Rearrangement Signature in High-Grade Serous Ovarian Cancer

As reported by Hillman et al in the Journal of the National Cancer Institute, a novel genomic rearrangement signature associated with poorer overall survival has been identified in high-grade serous ovarian cancer. Study Details In the study, clinical data and whole-genome sequencing results were ...

gynecologic cancers

CD8-Positive Tumor-Infiltrating Lymphocytes and Survival in High-Grade Serous Ovarian Cancer

As reported in JAMA Oncology by Goode et al in the Ovarian Tumor Tissue Analysis Consortium, higher levels of cytotoxic CD8-positive tumor-infiltrating lymphocytes were associated with significantly improved overall survival among women with high-grade serous ovarian carcinomas. Study Details The ...

gynecologic cancers

sNDA Submitted for Rucaparib as Maintenace Treatment for Patients With Platinum-Sensitive Recurrent Ovarian Cancer

On October 9, Clovis Oncology announced that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for rucaparib (Rubraca) as maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer...

gynecologic cancers

Role of the E7 Gene in High-Risk HPV

National Cancer Institute (NCI) researchers have found that for the most common high-risk type of human papillomavirus (HPV) to cause cervical cancer, an important viral gene may need to have a precise DNA sequence. The findings, published by Mirabello et al in Cell, contribute to a better...

gynecologic cancers

ASTRO 2017: GOG-249 Confirms Adjuvant Pelvic Radiation as Standard of Care for High-Risk, Early-Stage Endometrial Cancer

In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I–II high-risk endometrial cancer were not superior following adjuvant vaginal cuff brachytherapy plus chemotherapy when compared with...

gynecologic cancers

ASTRO 2017: IAEA Trial: Safety, Efficacy of High-Dose Brachytherapy Plus Pelvic Radiation for Cervical Cancer

Findings from a new multicenter, international clinical trial confirm the effectiveness of high-dose brachytherapy, or internal radiation therapy, for managing locally advanced cervical cancer. Tumor control was significantly better following four fractions of 7 Gy each than following two 9-Gy...

gynecologic cancers

Olaparib Receives Positive pCODR Recommendation for Treatment of BRCA-Mutated Ovarian Cancer

The pan-Canadian Oncology Drug Review (pCODR) has provided a positive clinical recommendation for the reimbursement of olaparib (Lynparza), a first-of-its-kind treatment for BRCA-mutated ovarian cancer. Lynparza is an oral, potent inhibitor of poly (ADP-ribose) polymerase (PARP) available as a...

gynecologic cancers

Final Efficacy Analysis of 9-Valent Human Papillomavirus Vaccine Trial

The final efficacy analysis of a trial of 9-valent human papillomavirus (HPV) vaccine has shown a high preventive effect against disease due to the additional HPV pathogenic strains covered compared with the quadrivalent vaccine at up to 6 years. These findings were reported by Huh et al in The...

cns cancers
gynecologic cancers
kidney cancer
lung cancer
gastroesophageal cancer

FDA Approves First Biosimilar for the Treatment of Cancer

The U.S. Food and Drug Administration today approved bevacizumab-awwb (Mvasi) as a biosimilar to bevacizumab (Avastin) for the treatment of multiple types of cancer. Bevacizumab-awwb is the first biosimilar approved in the U.S. for the treatment of cancer. “Bringing new biosimilars to...

gynecologic cancers

ESMO 2017: Study Confirms Chemoradiation Is Best Treatment for Locally Advanced Cervical Cancer

A 14-year randomized trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings were reported at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract 928O_PR). ...

gynecologic cancers

ESMO 2017: Rucaparib Boosts Progression-Free Survival in BRCA-Mutant Recurrent Ovarian Cancer

Rucaparib (Rubraca) maintenance therapy increases progression-free survival in BRCA-mutant recurrent ovarian cancer by 77%, according to late-breaking results from the ARIEL3 trial reported at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Abstract LBA40_PR). Most...

gynecologic cancers

ESMO 2017: ICON8 Trial Reaffirms Standard Chemotherapy Dosing in Ovarian Cancer

Caucasian women with ovarian cancer can safely stick to the standard every-3-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial presented at the European Society for Medical Oncology (ESMO) 2017 Congress in...

breast cancer
gynecologic cancers

Loss of Heterozygosity in BRCA Gene May Influence Survival in Breast and Ovarian Cancers

Researchers in the Perelman School of Medicine at the University of Pennsylvania have found a relationship between the genetics of tumors with germline BRCA1/2 mutations—and whether the tumor retains the normal copy of the BRCA1/2 gene—and risk for primary resistance to a common...

gynecologic cancers

FDA Approves Olaparib Tablets for Maintenance Treatment in Ovarian Cancer

On August 17, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to olaparib tablets (Lynparza) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to...

gynecologic cancers

Increased Endometrial Cancer Rates Found in Women With Increased Levels of Cadmium

Through a 5-year observational study recently published by McElory et al in PLOS One, researchers at the University of Missouri (MU) found that women with increased levels of cadmium—a metal commonly found in foods such as kidney, liver, and shellfish, as well as tobacco—had an...

gynecologic cancers

Final Overall Survival Results of GOG 240 Trial Adding Bevacizumab to Chemotherapy in Advanced Cervical Cancer

As reported in The Lancet by Tewari et al, the final overall survival results of the phase III Gynecologic Oncology Group (GOG) 240 trial show continued benefit of the addition of bevacizumab (Avastin) to chemotherapy in patients with metastatic, persistent, or recurrent cervical carcinoma. Study...

gynecologic cancers

New Device to Test for Cervical Cancer May Be Less Painful for Patients, Produce Better Results

When a woman has an abnormal Papanicolaou (Pap) smear, she usually undergoes colposcopy—a procedure physicians use to closely examine the cervix, vagina, and vulva for signs of disease. Typically, a metal instrument is used to obtain a small sampling of cells inside the cervix, which is...

gynecologic cancers

Olaparib Tablets as Maintenance in BRCA1/2-Mutant Platinum-Sensitive Relapsed Ovarian Cancer

A phase III trial (SOLO2/ENGOT-Ov21) has shown improved progression-free survival with an olaparib tablet formulation vs placebo as maintenance therapy in patients with BRCA1/2-mutant platinum-sensitive relapsed ovarian cancer. These study results were reported by Pujade-Lauraine et al in The...

gynecologic cancers

Current Performance Measures for Cervical Cancer Screening

Health-care systems use performance measures for cervical cancer screening based on guidelines from such organizations as the American College of Obstetricians and Gynecologists to monitor the appropriateness of cervical cancer screening. According to the performance measure in the Healthcare...

gynecologic cancers

Dutch Study Assesses Long-Term Risk of HPV-Related Carcinoma and Premalignancies After CIN3 Diagnosis

A Dutch study has shown long-lasting risk for human papillomavirus (HPV)-related carcinoma and premalignancies in women with a diagnosis of cervical intraepithelial neoplasia grade 3 (CIN3). The findings were reported by Ebisch et al in the Journal of Clinical Oncology. Study Details The...

gynecologic cancers

Tumor Microvessel Density and Outcome With Bevacizumab in Ovarian Cancer

A retrospective biomarker analysis of the phase III GOG-0218 trial indicated a higher tumor microvessel density was associated with progression-free and overall survival benefit with bevacizumab (Avastin) vs placebo plus front-line chemotherapy in patients with ovarian cancer. These findings were...

gynecologic cancers

Pembrolizumab in Advanced PD-L1–Positive Endometrial Cancer

Pembrolizumab (Keytruda) showed activity in previously treated patients with advanced programmed cell death ligand 1 (PD-L1)–positive endometrial cancer in a cohort of the phase Ib KEYNOTE-028 study. These findings were reported in the Journal of Clinical Oncology by Ott et al. Study Details ...

gynecologic cancers

Durvalumab With Olaparib or Cediranib in Women’s Cancers

As reported in the Journal of Clinical Oncology by Lee et al, a phase I study has shown activity of the combination of the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab with either the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) or vascular endothelial growth...

gynecologic cancers

ASCO 2017: HPV Vaccination May Reduce Oral HPV Infections but Is Still Underutilized

In one of the first large studies to explore the possible impact of human papillomavirus (HPV) vaccination on oral HPV infections, researchers found it may confer a high degree of protection. The study of young adults in the United States showed that the prevalence of high-risk HPV infection was...

gynecologic cancers
survivorship

ESTRO 2017: Cervical Cancer Survivors Frequently Suffer From Long-Term Fatigue, Insomnia, and Hot Flashes

Around half of women who have been treated for locally advanced cervical cancer suffer from symptoms of insomnia, fatigue, or hot flashes at some point, according to new research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference (Abstract OC-0051). Cervical...

gynecologic cancers

Adding Bevacizumab to Paclitaxel-Carboplatin in Recurrent Platinum-Sensitive Ovarian Cancer

In a phase III trial (NRG Oncology/Gynecologic Oncology Group GOG-0213 trial) reported in The Lancet Oncology, Coleman et al found evidence of an overall survival advantage with the addition of bevacizumab (Avastin) to paclitaxel-carboplatin in recurrent platinum-sensitive ovarian cancer. The...

gynecologic cancers

Low Cervical Cancer Screening Rates Found Among Women With Severe Mental Illness

Women enrolled in California's Medicaid program (Medi-Cal) who have been diagnosed with severe mental illness have been screened for cervical cancer at much lower rates than other women, according to a new study by researchers at the University of California, San Francisco (UCSF), published by...

gynecologic cancers

Study Associates Comorbidities With Survival Outcomes in Women With Ovarian Cancer

Research from epidemiologists at Roswell Park Cancer Institute, published by Minlikeeva et al in Cancer Causes & Control, suggests that hypertension and diabetes and the use of medications to treat these comorbidities may have an effect on survival outcomes in women with ovarian cancer. Study...

gynecologic cancers

Total Laparoscopic Hysterectomy vs Total Abdominal Hysterectomy for Stage I Endometrial Cancer

A multinational equivalence trial has shown no difference in disease-free survival with total laparoscopic hysterectomy vs total abdominal hysterectomy in women with treatment-naive stage I endometrial cancer. The findings were reported by Janda et al in JAMA. Study Details In the trial, 760...

breast cancer
gynecologic cancers

Significant Increase in Number of Women Tested for BRCA Gene, but Many High-Risk Patients Remain Unidentified

About 5% to 10% of breast cancer cases and 10% to 18% of ovarian cancer cases can be attributed to two BRCA genetic mutations. Testing for these genetic abnormalities has risen steadily over the past decade. Previously, mainly women with a history of cancer were referred for genetic testing, but as ...

gynecologic cancers

FDA Approves Maintenance Niraparib for Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose tumors have achieved complete or partial response to platinum-based chemotherapy....

gynecologic cancers

SGO 2017: Hospital Readmission Metrics May Not Be an Ideal Measure in Ovarian Cancer Cases

To reduce costs and improve quality of care, the Centers for Medicare & Medicaid Services (CMS) has made reducing hospital readmission rates a priority, yet two research studies presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer question the use...

gynecologic cancers

SGO 2017: Parental Concern About Lack of Sexual Activity Declining as Reason Not to Vaccinate Children Against HPV

Parental concern that a child is not sexually active is declining as a reason parents do not vaccinate their children against papillomavirus (HPV), according to a study presented by Beavis et al at the Society of Gynecologic Oncology’s (SGO) 2017 Annual Meeting on Women’s Cancer...

gynecologic cancers

SGO 2017: New Immunotherapy Axalimogene Filoslisbac Shows Positive Results in Cervical Cancer

A new immunotherapy drug, axalimogene filoslisbac (AXAL), showed improved survival rates for patients with cervical cancer, according to a study presented at the 2017 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer. Study coauthor Charles Leath, MD, MSPH, an SGO member ...

gynecologic cancers

SGO 2017: Secondary Endpoint Results of Phase III ENGOT-OV16/NOVA Trial of Niraparib in Recurrent Ovarian Cancer

Secondary endpoint results from the phase III ENGOT-OV16/NOVA trial of niraparib were presented at the 2017 Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, by Sven Mahner, MD, Director, Department of Gynecology and Obstetrics, University of Munich. “The results of...

Advertisement

Advertisement



Advertisement